Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions

Li Xiong; Deng, Xiaofeng; Yu Wen; Zhulin Yang; Xiongying Miao
June 2013
World Journal of Surgical Oncology;2013, Vol. 11 Issue 1, p1
Academic Journal
Background: Neurotrophic factors such as brain derived neurotrophic factor (BDNF) are synthesized in a variety of neural and non-neuronal cell types and regulate survival, proliferation and apoptosis. In addition, bone morphogenetic proteins (BMPs) inhibit the proliferation of pulmonary large carcinoma cells bone morphogenetic protein receptor, type IA (BMPR1A). Little is known about the expression of BDNF or BMPR1A in malignant gall bladder lesions. This study was to evaluate BDNF and BMPR1A expression and evaluate the clinicopathological significance in benign and malignant lesions of the gallbladder. Methods: The BDNF and BMPR1A expression of gallbladder adenocarcinoma, peritumoral tissues, adenoma, polyp and chronic cholecystitis were Immunohistochemically determined. Results: BDNF expression was significantly higher in gallbladder adenocarcinoma than in peritumoral tissues, adenoma, polyps and chronic cholecystitis samples. However, BMPR1A expression was significantly lower in gallbladder adenocarcinoma than in peritumoral tissues, adenomas, polyps and chronic cholecystitis tissues. The specimens with increased expression of BDNF in the benign lesions exhibited moderate- or severe-dysplasia of gallbladder epithelium. BDNF expression was significantly lower in well-differentiated adenocarcinomas with maximum tumor diameter <2 cm, no metastasis to lymph nodes, and no invasion of regional tissues compared to poorly-differentiated adenocarcinomas with maximal tumor diameter >2 cm, metastasis of lymph node, and invasiveness of regional tissues in gallbladder adenocarcinoma. BMPR1A expression were significantly higher in the well-differentiated adenocarcinoma with maximal tumor diameter <2 cm, no metastasis of lymph node, and no invasion of regional tissues compared to poorly-differentiated adenocarcinomas with maximal tumor diameter >2 cm, metastasis of lymph node, and invasiveness of regional tissues in gallbladder. Univariate Kaplan-Meier analysis indicated increased expression of BDNF or decreased expression of BMPR1A was associated with decreased disease specific survival (DSS) rates. Similarly, multivariate Cox regression analysis showed increased expression of BDNF or decreased expression of BMPR1A are independent predictors of poor DSS rates in gallbladder adenocarcinoma. Conclusions: In gallbladder malignancies, the increased expression of BDNF and decreased expression of BMPR1A were associated with increased risk of metastasis, regional invasion and mortality. They might serve as novel indicators of gallbladder adenocarcinoma outcomes, which may prove valuable for the development of personalized therapeutic paradigms.


Related Articles

  • Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. Yong-Seok Kim; Jeong-Soo Kim; Ja-Seong Bae; Woo-Chan Park // World Journal of Surgical Oncology;2013, Vol. 11 Issue 1, p1 

    Background: The BRAFV600E mutation is the most common genetic alteration in papillary thyroid carcinoma (PTC). In recent studies, the BRAFV600E mutation has been associated with poor clinicopathological characteristics, such as lymph node metastasis, extrathyroidal extension, and advanced stage....

  • BDNF: an indicator of insomnia? Giese, M; Unternährer, E; Hüttig, H; Beck, J; Brand, S; Calabrese, P; Holsboer-Trachsler, E; Eckert, A // Molecular Psychiatry;Feb2014, Vol. 19 Issue 2, p151 

    A letter to the editor is presented which clarifies the role of brain-derived neurotrophic factor (BDNF) levels with the symptoms of insomnia and non-sleep disturb controls for psychopathology.

  • BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Lu, Bai; Nagappan, Guhan; Guan, Xiaoming; Nathan, Pradeep J.; Wren, Paul // Nature Reviews Neuroscience;Jun2013, Vol. 14 Issue 6, p401 

    Increasing evidence suggests that synaptic dysfunction is a key pathophysiological hallmark in neurodegenerative disorders, including Alzheimer's disease. Understanding the role of brain-derived neurotrophic factor (BDNF) in synaptic plasticity and synaptogenesis, the impact of the BDNF Val66Met...

  • BDNF gene polymorphism, cognition and symptom severity in a Brazilian population-based sample of first-episode psychosis subjects. Martinho Jr., Eduardo; Michelon, Leandro; Ayres, Adriana M.; Scazufca, Marcia; Menezes, Paulo R.; Schaufelberger, Maristela S.; Murray, Robin M.; Rushe, Teresa M.; Vallada, Homero; Filho, Geraldo Busatto // Revista Brasileira de Psiquiatria;SUPOct2012, Vol. 34 Issue S2, pS219 

    Objective: To investigate the influence of brain-derived neurotrophic factor (BDNF) gene variations on cognitive performance and clinical symptomatology in first-episode psychosis (FEP). Methods: We performed BDNF val66met variant genotyping, cognitive testing (verbal fluency and digit spans)...

  • BDNF-TrkB signaling as a therapeutic target in neuropsychiatric disorders. Xin Du; Yeewen C. Wu; Hill, Rachel Anne // Journal of Receptor, Ligand & Channel Research;2014, Vol. 7, p61 

    Research evidence points to abnormal brain-derived neurotrophic factor (BDNF) signaling being a common and vital participant in the etiology and pathophysiology of many psychiatric disorders, including depression, schizophrenia, and bipolar disorder. To increase BDNF levels in patients is...

  • Regulation of brain-derived neurotrophic factor expression in neurons. Fei Zheng; Xianju Zhou; Changjong Moon; Hongbing Wang // International Journal of Physiology, Pathophysiology & Pharmacol;2012, Vol. 4 Issue 4, p188 

    Brain-derived neurotrophic factor (BDNF) plays critical roles in many aspects of brain functions, including cell survival, differentiation, development, learning and memory. Aberrant BDNF expression has also been implicated in numerous neurological disorders. Thus, significant effort has been...

  • A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia. Nurjono, Milawaty; Lee, Jimmy; Siow-Ann Chong // Clinical Psychopharmacology & Neuroscience;Aug2012, Vol. 10 Issue 2, p61 

    Brain-derived neurotrophic factor (BDNF), a neurotrophin known to be responsible for development, regeneration, survival and maintenance of neurons has been implicated in the pathophysiology of schizophrenia. This review seeks to complement previous reviews on biological roles of BDNF and...

  • Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Zhang, Xiang; Liang, Jun; Chen, Da; Xiu, Mei; Yang, Fu; Kosten, Therese; Kosten, Thomas // Psychopharmacology;Jul2012, Vol. 222 Issue 2, p277 

    Objective: Several lines of evidence suggest that brain-derived neurotrophic factor (BDNF) plays a critical role in activity-dependent neuroplasticity underlying learning and memory in the hippocampus. Schizophrenia has a range of cognitive deficits that may evolve from decreased BDNF, and this...

  • The Potential of Cerebrolysin in the Treatment of Schizophrenia. Flores, Gonzalo; Atzori, Marco // Pharmacology & Pharmacy;Jun2014, Vol. 5 Issue 7, p691 

    Schizophrenia and psychosis are psychiatric condition whose neural mechanisms are yet incompletely known, and for which pharmacological treatment is too often ineffective in a growing clinical cohort. Recently, dendritic morphological changes in arborization and dendritic spine density in limbic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics